These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19118282)

  • 21. [Roles of cytokines and growth factors in diabetic retinopathy].
    Yamashita H; Yamamoto T
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():202-6. PubMed ID: 15999707
    [No Abstract]   [Full Text] [Related]  

  • 22. Aldosterone blockade in chronic kidney disease.
    Hirsch JS; Drexler Y; Bomback AS
    Semin Nephrol; 2014 May; 34(3):307-22. PubMed ID: 25016401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Renin-aldosterone and bone metabolism].
    Ikeda K
    Clin Calcium; 2014 Jun; 24(6):885-91. PubMed ID: 24870840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
    Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
    Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury.
    Liu Y; Hirooka K; Nishiyama A; Lei B; Nakamura T; Itano T; Fujita T; Zhang J; Shiraga F
    Exp Eye Res; 2012 Mar; 96(1):116-23. PubMed ID: 22200488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aldosterone in vascular and metabolic dysfunction.
    Luther JM
    Curr Opin Nephrol Hypertens; 2016 Jan; 25(1):16-21. PubMed ID: 26575396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases.
    Weinberger MH; Luft FC
    Kidney Int; 2006 Dec; 70(12):2051-3. PubMed ID: 17136130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (Pro)renin receptor: a treatment target for diabetic retinopathy?
    Wilkinson-Berka JL; Campbell DJ
    Diabetes; 2009 Jul; 58(7):1485-7. PubMed ID: 19564461
    [No Abstract]   [Full Text] [Related]  

  • 29. Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy.
    Jerome JR; Deliyanti D; Suphapimol V; Kolkhof P; Wilkinson-Berka JL
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The involvement of aldosterone in cyclic stretch-mediated activation of NADPH oxidase in vascular smooth muscle cells.
    Ohmine T; Miwa Y; Takahashi-Yanaga F; Morimoto S; Maehara Y; Sasaguri T
    Hypertens Res; 2009 Aug; 32(8):690-9. PubMed ID: 19478813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aldosterone and inflammation.
    Gilbert KC; Brown NJ
    Curr Opin Endocrinol Diabetes Obes; 2010 Jun; 17(3):199-204. PubMed ID: 20422780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors?
    Ando H
    Hypertens Res; 2023 Apr; 46(4):1056-1057. PubMed ID: 36653520
    [No Abstract]   [Full Text] [Related]  

  • 33. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.
    Bauersachs J; Jaisser F; Toto R
    Hypertension; 2015 Feb; 65(2):257-63. PubMed ID: 25368026
    [No Abstract]   [Full Text] [Related]  

  • 34. The mineralocorticoid receptor and oxidative stress.
    Fiebeler A; Luft FC
    Heart Fail Rev; 2005 Jan; 10(1):47-52. PubMed ID: 15947891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Aldosterone exacerbates chronic renal insufficiency].
    Kristensen KE; Egfjord M
    Ugeskr Laeger; 2011 Jan; 173(4):267-70. PubMed ID: 21262170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond.
    Clermont A; Bursell SE; Feener EP
    J Hypertens Suppl; 2006 Mar; 24(1):S73-80. PubMed ID: 16601577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients.
    Keidar S; Gamliel-Lazarovich A; Kaplan M; Pavlotzky E; Hamoud S; Hayek T; Karry R; Abassi Z
    Circ Res; 2005 Oct; 97(9):946-53. PubMed ID: 16179584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aldosterone: effects on the kidney and cardiovascular system.
    Briet M; Schiffrin EL
    Nat Rev Nephrol; 2010 May; 6(5):261-73. PubMed ID: 20234356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy.
    Wilkinson-Berka JL; Rana I; Armani R; Agrotis A
    Clin Sci (Lond); 2013 May; 124(10):597-615. PubMed ID: 23379642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
    Black HR
    Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.